A new COVID-19 vaccine has been approved for Australians. Here's what to know
The Therapeutic Goods Administration has given Pfizer's new COVID-19 jab the green light. But what about vaccines from ...
As new COVID-19 strains emerge, how do vaccine manufacturers keep up with mutations of the virus?
New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...
Australian Associated Press2d
No, Japan has not declared a state of emergency after ‘nanobot discovery’ in COVID vaccines
Social media users are spreading new levels of misinformation based on discredited claims that nanobots are lurking in ...
Pharmaceutical Technology on MSN2d
A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Pfizer faces showdown with $1.5 billion activist investor after post-Covid share plunge
Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...
FiercePharma1d
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
Armed robbery in Revesby2d
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
Does the updated Pfizer COVID-19 vaccine protect against the XEC variant?
Bogoch says the latest vaccine was designed for a sublineage of Omicron called KP.2, which began circulating several months ...
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
He Made Pfizer a Household Name. Wall Street Wants More.
With Pfizer’s stock down sharply, an activist investor is pushing for CEO Albert Bourla to improve performance.